GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Cyclically Adjusted Revenue per Share

Swedish Orphan Biovitrum AB (OSTO:SOBI) Cyclically Adjusted Revenue per Share : kr44.54 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted revenue per share for the three months ended in Mar. 2024 was kr18.183. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr44.54 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Swedish Orphan Biovitrum AB's average Cyclically Adjusted Revenue Growth Rate was 18.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 25.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Swedish Orphan Biovitrum AB was 25.90% per year. The lowest was 22.30% per year. And the median was 24.35% per year.

As of today (2024-04-28), Swedish Orphan Biovitrum AB's current stock price is kr281.00. Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr44.54. Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio of today is 6.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Swedish Orphan Biovitrum AB was 21.25. The lowest was 4.89. And the median was 7.81.


Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.96 21.98 27.09 35.87 42.98

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.49 39.50 41.13 42.98 44.54

Competitive Comparison of Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio falls into.



Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=18.183/130.9575*130.9575
=18.183

Current CPI (Mar. 2024) = 130.9575.

Swedish Orphan Biovitrum AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.383 100.432 3.107
201409 2.390 100.161 3.125
201412 2.522 100.225 3.295
201503 3.096 99.950 4.056
201506 2.732 99.995 3.578
201509 2.806 100.228 3.666
201512 2.905 100.276 3.794
201603 4.511 100.751 5.863
201606 5.213 101.019 6.758
201609 4.157 101.138 5.383
201612 4.584 102.022 5.884
201703 4.944 102.022 6.346
201706 5.796 102.752 7.387
201709 5.665 103.279 7.183
201712 6.621 103.793 8.354
201803 6.939 103.962 8.741
201806 8.074 104.875 10.082
201809 8.171 105.679 10.126
201812 9.078 105.912 11.225
201903 10.781 105.886 13.334
201906 10.224 106.742 12.543
201909 9.458 107.214 11.553
201912 15.762 107.766 19.154
202003 14.913 106.563 18.327
202006 9.873 107.498 12.028
202009 9.537 107.635 11.603
202012 14.626 108.296 17.687
202103 11.706 108.360 14.147
202106 10.361 108.928 12.456
202109 12.110 110.338 14.373
202112 15.713 112.486 18.293
202203 15.814 114.825 18.036
202206 12.425 118.384 13.745
202209 12.589 122.296 13.481
202212 19.428 126.365 20.134
202303 16.717 127.042 17.232
202306 15.521 129.407 15.707
202309 16.211 130.224 16.302
202312 19.089 130.958 19.089
202403 18.183 130.958 18.183

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Swedish Orphan Biovitrum AB  (OSTO:SOBI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=281.00/44.54
=6.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Swedish Orphan Biovitrum AB was 21.25. The lowest was 4.89. And the median was 7.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines